长春高新(000661.SZ)：子公司吸附无细胞百白破b型流感嗜血杆菌联合疫苗临床试验申请获得批准

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Baike Biotechnology Co., Ltd. (referred to as "Baike Biotechnology"), received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its acellular pertussis-diphtheria-tetanus combined vaccine with Hib [1] Group 1 - The approved vaccine, referred to as "DTP-Hib combined vaccine," is designed to simultaneously prevent whooping cough, diphtheria, tetanus, and infections caused by Haemophilus influenzae type b [1] - The target recipients of the vaccine are infants aged 2 months and older, and it is intended to stimulate the immune response to prevent invasive infections caused by these pathogens [1]